The drug regulator had on August 20 given emergency use authorisation (EUA) to the three-dose Covid-19 vaccine, the first in India that can...

Zydus Cadila has the drug regulator's emergency use authorisation to administer its Covid vaccine, ZyCoV-D, in children aged 12-18 years. A...

Needle-free ZyCoV-D, manufactured by Ahmedabad-based Zydus Cadila, is the first Covid-19 vaccine approved for the 12 to 18 years age group ...

The country's health authorities had given emergency approval in August for Cadila's vaccine, the world's first COVID-19 DNA shot, in adult...

Zydus Cadila's indigenously-developed needle-free COVID-19 vaccine ZyCoV-D received the Emergency Use Authorisation from the Drugs Controll...

Analysts do see a lift to its sales, even as some of them are not factoring in sales beyond FY23 amid uncertainty over booster shots. The p...

"Post the emergency use authorisation, now we will work closely with the regulatory authorities to work on the pricing and modality of deli...

Zydus Cadila last month had said that it has applied for emergency use authorisation (EUA) with the Indian Drug regulator for its three-dos...

The drug regulator will consider emergency use approval for Covid vaccines developed by Zydus Cadila for children above 12 this week. The r...

The Ahmedabad-based company is carrying out clinical trials involving 1,000 children to test the efficacy of its vaccine against SARS-CoV-2...

This week India overtook the US in daily addition of new COVID-19 cases. It is worrying. The World Health Organization says that the infect...

Cadila's vaccine candidate, known as ZyCov-D, is one of dozens being developed around the world to fight the coronavirus pandemic.

Through this agreement, Zydus gains access to the public and private market segments in the Russian Federation, Belarus, Uzbekistan, Kazakh...

Cadila Pharmaceuticals has developed a cancer vaccine and has filed for its therapeutic patent with Controller General of Patents Designs a...

Drug maker Zydus Cadila on Monday said it has received approval from the Drug Controller General of India (DCGI) for conducting clinical tr...

Ahmedabad-based Rs 800-crore Cadila Pharmaceuticals Ltd is all geared up for a large pie in the $665-million vaccine market in India.

US-based biotechnology firm Novavax has formed a joint venture with Cadila Pharmaceuticals for developing and commercialising virus-like pa...